References

  1. Martin JP. The basal ganglia and posture. London: Pitman Medical Publishing, 1967.
  2. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003;991:1-14.
  3. Lewy FH. Die Lehre vom Tonus und der Bewegung zugleich systematische Untersuchungen zur Klinik, Physiologie, Pathologie und Pathogenese der Paralysis Agitans. Berlin: Julius Springer, 1923.
  4. Falck B, Hillarp NA, Thieme G, Torp A. Fluorescence of catecholamine and related compounds condensed with formaldehyde. J Histochem Cytochem 1962;10:348-354.
  5. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426.
  6. Jellinger KA. Post mortem studies in Parkinson's disease—is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl 1999;56:1-29.
  7. Jellinger KA, Mizuno Y.Parkinson's disease. In: Dickson D, eds. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003.
  8. Hunter R, Smith J, Thomson T, Dayan AD. Hemiparkinsonism with infarction of the ipsilateral substantia nigra. Neuropathol Appl Neurobiol 1978;4:297-301.
  9. Gherardi R, Roualdes B, Fleury J, Prost C, Poirier J, Degos JD. Parkinsonian syndrome and central nervous system lymphoma involving the substantia nigra. A case report. Acta Neuropathol (Berl) 1985;65:338-343.
  10. Josephs KA, Ishizawa T, Tsuboi Y, Cookson N, Dickson DW. A clinicopathological study of vascular progressive supra-nuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy. Arch Neurol 2002;59:1597-1601.
  11. Wilson SAK. An experimental research into the anatomy and physiology of the corpus striatum. Brain 1914;36:437.
  12. Russmann H, Vingerhoets F, Ghika J, Maeder P, Bogousslavsky J. Acute infarction limited to the lenticular nucleus: clinical, etiologic, and topographic features. Arch Neurol 2003;60:351-355.
  13. Chang CM, Yu YL, Ng HK, Leung SY, Fong KY. Vascular pseudoparkinsonism. Acta Neurol Scand 1992;86:588-592.
  14. Adhiyaman V, Meara J. Meningioma presenting as bilateral parkinsonism. Age Ageing 2003;32:456-458.
  15. Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson's disease. Neuropathol Appl Neurobiol 1989;15:27-44.
  16. Shimura H, Schlossmacher MG, Hattori N, et al. Ubiquitination of a new form of a—synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001;293:263-269.
  17. Calne D. Parkinson's disease is not one disease. Parkinsonism Relat Disord 2000;7:3-7.
  18. Armstrong RA, Cairns NJ, Lantos PL. Are pathological lesions in neurodegenerative disorders the cause or the effect of the degeneration? Neuropathology 2002;22:133-146.
  19. Tretiakoff C. Contribution à l'étude de l'anatomie pathologique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles du tonus musculaire et de la maladie de Parkinson; Medical Thesis, Paris: Jouve et Cie, 1919:124p.
  20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
  21. Okazaki H, Lipkin LE, Aronson SM. Diffuse intracytoplasmic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961;20:237-244.
  22. Duffy PE, Tennyson VM. Phase and electron microscopic observations of Lewy bodies and melanin granules in the substantia nigra and locus caeruleus in Parkinson's disease. J Neuropathol Exp Neurol 1965;24:398-414.
  23. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-191.
  24. Lowe J, Blanchard A, Morrell K, et al. Ubiquitin is common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 1988;155:9-15.
  25. Ii K, Ito H, Tanaka K, Hirano A. Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. J Neuropathol Exp Neurol 1997;56:125-131.
  26. Maroteaux L, Campanelli JT, Scheller RH. Synuclein: a neuron-specific protein localized to the nucleus and presynap-tic nerve terminal. J Neurosci 1988;8:2804-2815.
  27. Ueda K, Fukushima H, Masliah E, et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 1993;90:11282-11286.
  28. George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995;15:361-372.
  29. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a—synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
  30. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. A—synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998;95:6469-6473.
  31. Uchikado H, Iseki E, Tsuchiya K, et al. Dementia with Lewy bodies showing advanced Lewy pathology but minimal Alzheimer pathology—Lewy pathology causes neuronal loss inducing progressive dementia. Clin Neuropathol 2002;21:269-277.
  32. Gomez-Isla T, Growdon WB, McNamara M, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003-2009.
  33. Kosaka K, Tsuchiya K, Yoshimura M. Lewy body disease with and without dementia: a clinicopathological study of 35 cases. Clin Neuropathol 1988;7:299-305.
  34. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree—a new disease? Clin Neuropathol 1984;3:185-192.
  35. Kosaka K. Diffuse Lewy body disease in Japan. J Neurol 1990;237:197-204.
  36. Braak H, Braak E, Yilmazer D, Schultz C, Devos RAI, Jansen ENH. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm 1995;Supp 46:15-31.
  37. Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284-1291.
  38. Marui W, Iseki E, Nakai T, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 2002;195:153-159.
  39. Rajput AH, Rozdilsky B. Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry 1976;39:1092-1100.
  40. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999;52:1269-1271.
  41. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (Berl) 1988;76:217-221.
  42. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-148.
  43. Hakim AM, Mathieson G. Dementia in Parkinson disease: a neuropathologic study. Neurology 1979;29:1209.
  44. Boller F, Mizutani R, Roessmann U, Gambetti P. Parkinson's disease, dementia and Alzheimer's disease: clinico-pathological correlations. Ann Neurol 1980;1:329-355.
  45. Gaspar P, Gray F. Dementia in idiopathic Parkinson disease. A neuropathological study of 32 cases. Acta Neuropathol (Berl) 1984;64:43-52.
  46. Mattila PM, Roytta M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson's disease. Acta Neuropathol (Berl) 1998;95:576-582.
  47. Jendroska K, Kashiwagi M, Sassoon J, Daniel SE. Amyloid beta-peptide and its relationship with dementia in Lewy body disease. J Neural Transm Suppl 1997;51:137-144.
  48. Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002;109:329-339.
  49. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
  50. Gibb WR, Lees AJ. Prevalence of Lewy bodies in Alzheimer's disease. Ann Neurol 1989;26:691-693.
  51. Bergeron C, Pollanen M. Lewy bodies in Alzheimer disease—one or two diseases? Alzheimer Dis Assoc Disord 1989;3:197-204.
  52. Mirra SS. Neuropathological assessment of Alzheimer's disease: the experience of the Consortium to Establish a Registry for Alzheimer's Disease. Int Psychogeriatr 1997;9:263-268; discussion 269-272.
  53. Heyman A, Fillenbaum GG, Gearing M, et al. Comparison of Lewy body variant of Alzheimer's disease with pure Alzheimer's disease: Consortium to Establish a Registry for Alzheimer's Disease, Part XIX. Neurology 1999;52:1839-1844.
  54. Schmidt ML, Martin JA, Lee VM, Trojanowski JQ. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol 1996;91:475-481.
  55. Hansen LA, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer disease is usually the Lewy body variant and vice versa. J Neuropathol Exp Neurol 1993;52:648-654.
  56. Gearing M, Lynn M, Mirra SS. Neurofibrillary pathology in Alzheimer disease with Lewy bodies: two subgroups. Arch Neurol 1999;56:203-208.
  57. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease : a clinical and pathologic entity. Neurology 1990;40:1-8.
  58. Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in elderly. J Neurol Sci 1990;95:119-139.
  59. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) : report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124.
  60. McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies. Neurology 1999;53:902-905.
  61. Lantos PL, Ovenstone IM, Johnson J, Clelland CA, Roques P, Rossor MN. Lewy bodies in the brain of two members of a family with the 717 (Val to Ile) mutation of the amyloid precursor protein gene. Neurosci Lett 1994;172:77-79.
  62. Lippa CF, Fujiwara H, Mann DMA, et al. Lewy bodies contain altered a—synuclein in brains of many familiar Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365-1370.
  63. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to a—synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999;45:353-357.
  64. Perl DP, Olanow CW, Calne D. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann Neurol 1998;44:S19-S31.
  65. Egensperger R, Bancher C, Kosel S, Jellinger K, Mehraein P, Graeber MB. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun 1996;224:484-486.
  66. Inzelberg R, Chapman J, Treves TA, et al. Apolipoprotein E4 in Parkinson disease and dementia: new data and metaanalysis of published studies. Alzheimer Dis Assoc Disord 1998;12:45-48.
  67. Gearing M, Schneider JA, Rebeck GW, Hyman BT, Mirra SS. Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Neurology 1995;45:1985-1990.
  68. Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and a—synuclein. Science 2003;300:636-640.
  69. Adams RD, Bogaert van L, Vander Eecken H. Dégénérescences nigro-striées et cérébello-nigro-striées. Psychiatria et Neurologia 1961;142:219.
  70. Adams RD, Bogaert van L, Vander Eecken H. Striato-nigral degeneration. J Neuropathol Exp Neurol 1965;23:584-608.
  71. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
  72. Konigsmark BW, Weiner LP. The olivopontocerebellar atrophies: a review. Medicine (Baltimore) 1970;49:227-241.
  73. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32:28-34.
  74. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94:79-100.
  75. Costa C, Duyckaerts C, Cervera P, Hauw J-J. Les inclusions oligodendrogliales, un marqueur des atrophies multisystématisées. Rev Neurol (Paris) 1992;148:274-280.
  76. Mori F, Tanji K, Yoshimoto M, Takahashi H, Wakabayashi K. Demonstration of a-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment. Exp Neurol 2002;176:98-104.
  77. Kahle PJ, Neumann M, Ozmen L, et al. Hyperphosphorylation and insolubility of a-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3:583-588.
  78. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A 1988;85:4051-4055.
  79. Buée L, Delacourte A. Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol 1999;9:681-693.
  80. Delacourte A, Buee L. Tau pathology: a marker of neurodegenerative disorders. Curr Opin Neurol 2000;13:371-376.
  81. Vermersch P, Frigard B, Delacourte A. Mapping of neurofibrillary degeneration in Alzheimer's disease—evaluation of heterogeneity using the quantification of abnormal tau proteins. Acta Neuropathol (Berl) 1992;85:48-54.
  82. Delacourte A, Defossez A. Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly are major components of paired helical filaments. J Neurol Sci 1986;76:173-186.
  83. Buee-Scherrer V, Buee L, Leveugle B, Perl DP, Vermersch P, Hof PR, Delacourte A. Pathological tau proteins in postencephalitic parkinsonism: comparison with Alzheimer's disease and other neurodegenerative disorders. Ann Neurol 1997;42:356-359.
  84. Flament S, Delacourte A, Verny M, Hauw J-J, Javoy-Agid F. Abnormal tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type. Acta Neuropathol (Berl) 1991;591-596.
  85. Togo T, Sahara N, Yen SH, et al. Argyrophilic grain disease is a sporadic 4-repeat tauopathy. J Neuropathol Exp Neurol 2002;61:547-556.
  86. Buée-Scherrer V, Hof PR, Buée L, et al. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease. Acta Neuropathol (Berl) 1996;91:351-359.
  87. Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation. Am J Pathol 2003;162:213-218.
  88. Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002;22:9340-9351.
  89. Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J Neurochem 1999;72:1243-1249.
  90. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy; a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuclear dystonia and dementia. Arch Neurol 1964;10:333-359.
  91. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Transact Am Neurol Assoc 1967;92:23-26.
  92. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968;18:20-33.
  93. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 1997;41:277-281.
  94. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999;8:711-715.
  95. Houlden H, Baker M, Morris HR, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001;56:1702-1706.
  96. Steele JC. Progressive supranuclear palsy. Historical notes. J Neural Transm Suppl 1994;42:3-14.
  97. Wenning GK, Jellinger K, Litvan I. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. J Neural Transm 1997;104:845-865.
  98. Geddes JF, Hugues AJ, Lees AJ, Daniel SE. Pathological overlap in cases of Parkinsonism associated with neurofibril-lary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear and Guamanian parkinsonism-dementia complex. Brain 1993;116:1-22.
  99. Brion JP, Passareiro H, Nunez J, Flament-Durand J. Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer. Arch Biol (Brux) 1985;95:229-235.
  100. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan H, Wiesniewski HM. Abnormal phosphorylation of the microtubule associated protein (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913-4917.
  101. Bancher C, Lassmann H, Budka H, et al. Neurofibrillary tangles in Alzheimer's disease and progressive supranuclear palsy; antigenic similarities and differences. Acta Neuropathol (Berl) 1987;74:39.
  102. Gallyas F. Silver staining of Alzheimer's neurofibrillary changes by means of physical development. Acta Morphol Acad Sci Hung 1971;19:1-8.
  103. Probst A, Langui D, Lautenschlager C, Ulrich J, Brion JP, Anderton BH. Progressive supranuclear palsy: extensive neuropil threads in addition to neurofibrillary tangles. Very similar antigenicity of subcortical neuronal pathology in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathol (Berl) 1988;77:61-68.
  104. Ikeda K, Akiyama H, Haga C, Kondo H, Arima K, Oda T. Argyrophilic thread-like structure in corticobasal degeneration and supranuclear palsy. Neurosci Letters 1994;174:157-159.
  105. Ikeda K, Akiyama H, Aral T, Nishimura T. Glial tau pathology in neurodegenerative diseases; their nature and comparison with neuronal tangles. Neurobiol Aging 1998;19:S85-S91.
  106. Arima K, Nakamura M, Sunohara N, et al. Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathol (Berl) 1997;93:558-566.
  107. Braak H, Braak E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 1989;15:13-26.
  108. Matsusaka H, Ikeda K, Akiyama H, Arai T, Inoue M, Yagishita S. Astrocytic pathology in progressive supranuclear palsy: significance for neuropathological diagnosis. Acta Neuropathol (Berl) 1998;96:248-252.
  109. Hauw J-J, Verny M, Delaère P, Cervera P, He Y, Duyckaerts C. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett 1990;119:182-186.
  110. Hauw J-J, Agid Y. Progressive Supranuclear Palsy (PSP) or Steele-Richardson-Olszewski Disease. In: Dickson D, eds. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press, 2003.
  111. Abe H, Yagishita S, Amano N, Bise K. Ultrastructural and immunohistochemical study of "astrocytic tangles" (ACT) in patients with progressive supranuclear palsy. Clin Neuropathol 1992;5:278.
  112. Yamada T, McGeer PL, McGeer EG. Appearance of paired nucleated, Tau positive glia in patients with progressive supranuclear palsy brain tissue. Neurosci Lett 1992;135:99-102.
  113. Yamada T, Calne DB, Akiyama H, McGeer PL. Further observations on tau-postive glia in the brains with progressive supranuclear palsy. Acta Neuropathol (Berl) 1993;85:308-315.
  114. Hattori M, Hashizume Y, Yoshida M, et al. Distribution of astrocytic plaques in the corticobasal degeneration brain and comparison with tuft-shaped astrocytes in the progressive supranuclear palsy brain. Acta Neuropathol 2003;106:143-149.
  115. Tellez-Nagel I, Wisniewski HM. Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome. Arch Neurol 1973;29:324-327.
  116. Bugiani O, Mancardi GL, Brusa A, Ederli A. The fine structure of subcortical neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol (Berl) 1979;45:147-152.
  117. Tomonaga M. Ultrastructure of neurofibrillary tangles in progressive supranuclear palsy. Acta Neuropathol (Berl) 1977;37:177-181.
  118. Yagishita S, Itoh Y, Amano N, Nakano T, Saitoh A. Ultrastructure of neurofibrillary tangles in progressive supra-nuclear palsy. Acta Neuropathol (Berl) 1979;48:27-30.
  119. Takahashi M, Weidenheim KM, Dickson DW, Ksiezak-Reding H. Morphological and biochemical correlations of abnormal tau filaments in progressive supranuclear palsy. J Neuropathol Exp Neurol 2002;61:33-45.
  120. Verny M, Duyckaerts M, Delaère M, He Y, Hauw J-J. Cortical tangles in progressive supranuclear palsy. J Neural Transm 1994;(Suppl)42:179-188.
  121. Verny M, Duyckaerts C, Agid Y, Hauw J-J. The significance of cortical pathology in progressive supranuclear palsy. Brain 1996;119:1123-1136.
  122. Hauw J-J, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019.
  123. Dubas F, Gray F, Escourolle R. Maladie de Steele-Richardson-Olszewski sans ophtalmoplégie; six cas anatomo-cliniques. Rev Neurol (Paris) 1983;139:407-416.
  124. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord 2002;17:1255-64.
  125. Cambier J, Masson M, Viader J, Limodin J, Strube A. Le syndrome frontal de la paralysie supranucléaire progressive. Rev Neurol (Paris) 1985;141:537-545.
  126. Davis PH, Bergeron C, McLachlan DR. Atypical presentation of progressive supranuclear palsy. Ann Neurol 1985;17:337-343.
  127. Litvan I. Cognitive disturbances in progressive supranuclear palsy. J Neural Transm 1994;42(Suppl):69-78.
  128. Bergeron C, Davis A, Lang AE. Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. Brain Pathol 1998;8:355-365.
  129. Bigio EH, Brown DF, White CL, III. Progressive supranuclear palsy with dementia: cortical pathology. J Neuropathol Exp Neurol 1999;58:359-364.
  130. Foster NL, Sima AAF, D'Amato C, et al. Cerebral cortical pathology in progressive supranuclear palsy is correlated with severity of dementia. Neurology 1996;46:A363.
  131. Boeve B, Dickson D, Duffy J, Bartleson J, Trenerry M, Petersen R. Progressive nonfluent aphasia and subsequent aphasic dementia associated with atypical progressive supranuclear palsy pathology. Eur Neurol 2003;49:72-78.
  132. Rafal RD, Friedman JH. Limb dystonia in progressive supranuclear palsy. Neurology 1987;37:1546-1549.
  133. Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration in progressive supranuclear palsy. A comparison with cortico-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997;56:726-735.
  134. Cordato NJ, Halliday GM, McCann H, Davies L, Williamson P, Fulham M, Morris JG. Corticobasal syndrome with tau pathology. Mov Disord 2001;16:656-67.
  135. Leiguarda RC, Pramstaller PP, Merello M, Starkstein S, Lees AJ, Marsden CD. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain 1997;120:75-90.
  136. Caparros-Lefebvre D, Sergeant N, Lees A, Camuzat A, Daniel S, Lannuzel A, Brice A, Tolosa E, Delacourte A, Duyckaerts C. Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002;125:801-811.
  137. Caparros-Lefebvre D, Elbaz A. Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group. Lancet 1999;354:281-286.
  138. Cambier J, Masson M, Dairou R, Henin D. Etude anatomo-clinique d'une forme pariétale de maladie de Pick. Rev Neurol (Paris) 1981;137:33-38.
  139. Tsuchiya K, Ikeda M, Hasegawa K, et al. Distribution of cerebral cortical lesions in Pick's disease with Pick bodies: a clinicopathological study of six autopsy cases showing unusual clinical presentations. Acta Neuropathol (Berl) 2001;102:553-571.
  140. Gibb WRG, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989;112:1171-1192.
  141. Horoupian DS, Chu PL. Unusual case of corticobasal degeneration with tau/Gallyas-positive neuronal and glial tangles. Acta Neuropathol (Berl) 1994;88:592-598.
  142. Uchihara T, Mitani K, Mori H, Kondo H, Yamada M, Ikeda K. Abnormal cytoskeletal pathology peculiar to corticobasal degeneration is different from that of Alzheimer's disease or progressive supranuclear palsy. Acta Neuropathol (Berl) 1994;88:379-383.
  143. Mori H, Nishimura N, Namba Y, Oda M. Corticobasal degeneration: a disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy. Acta Neuropathol (Berl) 1994;88:113-121.
  144. Feany MB, Dickson DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol 1995;146:1388-1396.
  145. Daniel SE, Geddes F, Revesz T. Clinicopathological overlap between cases of Pick's disease and corticobasal degeneration. Brain Pathology 1994;4:516.
  146. Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol 1996;55:53-67.
  147. Ikeda K, Akiyama H, Iritani S, et al. Corticobasal degeneration with primary progressive aphasia and accentuated cortical lesion in superior temporal gyrus: case report and review. Acta Neuropathol (Berl) 1996;92:534-539.
  148. Arai T, Ikeda K, Akiyama H, et al. Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol (Berl) 2003;105:489-498.
  149. de Silva R, Lashley T, Gibb G, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003;29:288-302.
  150. Komori T, Arai N, Oda M, et al. Morphologic difference of neuropil threads in Alzheimer's disease, corticobasal degeneration and progressive supranuclear palsy: a morphometric study. Neurosci Lett 1997;233:89-92.
  151. Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999;246 Suppl 2:II6-II15:
  152. Tolnay M, Probst A. Tau protein pathology in Alzheimer's disease and related disorders. Neuropathol Appl Neurobiol 1999;25:171-187.
  153. Komori T, Shibata N, Kobayashi M. Plaque-like structures in the cerebral cortex of corticobasal degeneration: a histo-pathological marker? Neuropathology 1995;15:175-176.
  154. Komori T, Arai N, Oda M, et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 1998;96:401-408.
  155. Dickson DW, Bergeron C, Chin SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol 2002;61:935-46.
  156. Shiozawa M, Fukutani Y, Sasaki K, et al. Corticobasal degeneration: an autopsy case clinically diagnosed as progressive supranuclear palsy. Clin Neuropathol 2000;19:192-199.
  157. Mimura M, Oda T, Tsuchiya K, et al. Corticobasal degeneration presenting with nonfluent primary progressive aphasia: a clinicopathological study. J Neurol Sci 2001;183:19-26.
  158. Tsuchiya K, Ikeda K, Uchihara T, Oda T, Shimada H. Distribution of cerebral cortical lesions in corticobasal degeneration: a clinicopathological study of five autopsy cases in Japan. Acta Neuropathol (Berl) 1997;94:416-424.
  159. Grimes DA, Lang AE, Bergeron CB. Dementia as the most common presentation of cortical-basal ganglionic degeneration. Neurology 1999;53:1969-1974.
  160. Dickson D, Litvan I. Corticobasal degeneration. In: Dickson D, ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003.
  161. Katsuse O, Iseki E, Arai T, et al. 4-repeat tauopathy sharing pathological and biochemical features of corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 2003;11:11.
  162. Togo T, Dickson DW. Ballooned neurons in progressive supranuclear palsy are usually due to concurrent argyrophilic grain disease. Acta Neuropathol (Berl) 2002;104:53-56.
  163. Ishizawa T, Ko LW, Cookson N, Davias P, Espinoza M, Dickson DW. Selective neurofibrillary degeneration of the hippocampal CA2 sector is associated with four-repeat tauopathies. J Neuropathol Exp Neurol 2002;61:1040-1047.
  164. Morris JC, Drazner M, Fulling K, Grant EA, Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch Neurol 1989;46:651-657.
  165. Daniel SD, Lees AJ. Neuropathological features of Alzheimer's disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry 1991;54:971-975.
  166. Braak H, Braak E. Alzheimer's disease: striatal amyloid deposits and neurofibrillary changes. J Neuropathol Exp Neurol 1990;49:215-224.
  167. Schneider JA, Bienias JL, Gilley DW, Kvarnberg DE, Mufson EJ, Bennett DA. Improved detection of substantia nigra pathology in Alzheimer's disease. J Histochem Cytochem 2002;50:99-106.
  168. Liu Y, Stern Y, Chun MR, Jacobs DM, Yau P, Goldman JE. Pathological correlates of extrapyramidal signs in Alzheimer's disease. Ann Neurol 1997;41:368-374.
  169. Kemppainen N, Roytta M, Collan Y, Ma SY, Hinkka S, Rinne JO. Unbiased morphological measurements show no neuronal loss in the substantia nigra in Alzheimer's disease. Acta Neuropathol (Berl) 2002;103:43-47.
  170. Lyness SA, Zarow C, Chui HC. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a metaanalysis. Neurobiol Aging 2003;24:1-23.
  171. Stern Y, Jacobs D, Goldman J, et al. An investigation of clinical correlates of Lewy bodies in autopsy-proven Alzheimer disease. Arch Neurol 2001;58:460-465.
  172. Corsellis JAN, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med 1973;3:270-303.
  173. Geddes JF, Vowles GH, Robinson SFD, Sutcliffe JC. Neurofibrillary tangles, but not Alzheimer-type pathology, in a young boxer. Neuropathol Appl Neurobiol 1996;22:12-16.
  174. Geddes JF, Vowles GH, Nicoll JA, Revesz T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol (Berl) 1999;98:171-178.
  175. Reid AH, McCall S, Henry JM, Taubenberger JK. Experimenting on the past: the enigma of von Economo's encephalitis lethargica. J Neuropathol Exp Neurol 2001;60:663-670.
  176. Litvan II, Jankovic J, Goetz CG, et al. Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinico-pathologic study. Eur J Neurol 1998;5:451-457.
  177. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE, Fanning TG. Initial genetic characterization of the 1918 "Spanish" influenza virus. Science 1997;275:1793-1796.
  178. Ikeda K, Akiyama H, Kondo H, Ikeda K. Anti-tau-positive glial fibrillary tangles in the brain of postencephalitic parkinsonism of Economo type. Neurosci Lett 1993;162:176-178.
  179. Haraguchi T, Ishizu H, Terada S, et al. An autopsy case of postencephalitic parkinsonism of von Economo type: some new observations concerning neurofibrillary tangles and astrocytic tangles. Neuropathology 2000;20:143-148.
  180. Geddes JF, Hughes AJ, Lees AJ, Daniel SE. Pathological overlap in cases of parkinsonism associated with neurofibril-lary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. Brain 1993;116:281-302.
  181. Oyanagi K. Parkinsonism-dementia complex of Guam. In: Dickson D, ed. Neurodegeneration: the Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003.
  182. Oyanagi K, Wada M. Neuropathology of parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam: an update. J Neurol 1999;246(Suppl 2):19-27.
  183. Perl DP.Amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. In: Markesbery WR, ed. Neuropa-thology of Dementing Disorders. London: Arnold, 1998.
  184. Hirano A, Kurland LT, Krooth RS, Lessell S. Parkinsonism-dementia complex, an endemic disease on the island of Guam. I. Clinical features. Brain 1961;84:642-661.
  185. Hirano A, Malamud N, Kurtland LT. Parkinsonism-dementia complex, an endemic disease of island of Guam. II.-Pathological features. Brain 1961;84:662-679.
  186. Morris HR, Al-Sarraj S, Schwab C, et al. A clinical and pathological study of motor neurone disease on Guam. Brain 2001;124:2215-2222.
  187. Schwab C, Schulzer M, Steele JC, McGeer PL. On the survival time of a tangled neuron in the hippocampal CA4 region in parkinsonism dementia complex of Guam. Neurobiol Aging 1999;20:57-63.
  188. Oyanagi K, Makifuchi T, Ohtoh T, Chen KM, Gajdusek DC, Chase TN. Distinct pathological features of the gallyas-and tau-positive glia in the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. J Neuropathol Exp Neurol 1997;56:308-316.
  189. Spencer PS, Nunn PB, Hugon J, et al. Guam amyotrophic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science 1987;237:517-522.
  190. Duncan MW, Steele JC, Kopin IJ, Markey SP. 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology 1990;40:767-772.
  191. Lüers T, Spatz H. Picksche Krankheit (Progressive umschriebene Grosshirnatrophie). In: Lubarsch O, Henke F, Rössle R, eds. Hanbuch der speziellen pathologischen Anatomie und Histologie. Berlin: Springer-Verlag, 1957.
  192. Onari K, Spatz H. Anatomische Beiträge zur Lehre von der Pickschen umschriebenen Grosshirnrinde-Atrophie ("Picksche Krankheit"). Z ges Neurol 1926;101:470-511.
  193. Escourolle R. La maladie de Pick. Etude critique d'ensemble et synthèse anatomo-clinique. Paris: R.Foulon, 1958.
  194. Pick A. Beiträge zur Pathologie und pathologischen Anatomie des Zentralnervensystems. Berlin: S. Karger, 1898.
  195. Pick A. Senile Hirnatrophie als Grundlage von Herderscheinungen. Wiener klinische Wschr 1901;14:16-17.
  196. Pick A. Uber einen weiteren Symptomencomplex im Rahmen der Dementia senilis, bedingt durch umschriebene stärkere Hirnatrophie (gemischte Apraxie). Mschr Psychiat Neurol 1906;19:97-108.
  197. Pick A. Ueber die Beziehungen der senilen Hirnatrophie zur Aphasie. Prager Med Wschr 1892;17:15-17.
  198. Alzheimer A. Uber eigenartige Krankheitsfälle des späteren Alters. Zentralblatt Gesam Neurol Psychiat 1911;4:356-385.
  199. Alzheimer A, Förstl H, Levy R. On certain peculiar diseases of old age. Hist Psychiatry 1991;2:71-101.
  200. Arai T, Ikeda K, Akiyama H, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl) 2001;101:167-73.
  201. Zhukareva V, Mann D, Pickering-Brown S, et al. Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann Neurol 2002;51:730-739.
  202. Komori T. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease. Brain Pathol 1999;9:663-679.
  203. Kertesz A, Hudson L, Mackenzie IRA, Munoz DG. The pathology and nosology of primary progressive aphasia. Neurology 1994;44:2065-2075.
  204. Kertesz A, Munoz D. Clinical and pathological characteristics of primary progressive aphasia and frontal dementia. Neural Transm (Suppl) 1996;47:133-141.
  205. Kertesz A. Pick complex and Pick's disease, the nosology of frontal lobe dementia, primary progressive aphasia, and corticobasal ganglionic degeneration. Eur J Neurol 1996;3:280-282.
  206. Kertesz A, Munoz D. Clinical and pathological overlap between frontal dementia, progressive aphasia and corticobasal degeneration. The Pick complex. Neurology 1997;48:293.
  207. Kertesz A. Frontotemporal dementia, Pick disease, and corticobasal degeneration. One entity or 3? Arch Neurol 1997;54:1427-1429.
  208. Kertesz A, Munoz D. Pick's disease, frontotemporal dementia, and Pick complex: emerging concepts. Arch Neurol 1998;55:302-304.
  209. Kertesz A, Munoz DG. Primary progressive aphasia and Pick complex. J Neurol Sci 2003;206:97-107.
  210. Duyckaerts C, Dürr A, Uchihara T, Boller F, Hauw J-J. Pick complex: too simple? Eur J Neurol 1996; 3:283-286.
  211. Duyckaerts C, Hauw JJ. Diagnostic controversies: another view. Adv Neurol 2000;82:233-240.
  212. Kertesz A, Munoz DG, Hillis A. Preferred terminology. Ann Neurol 2003;54(Supp 5):S3-S6.
  213. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol 1997;41:706-715.
  214. Hutton MJ, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998;393:702-705.
  215. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A 1998;95:7737-7741.
  216. Ghetti B, Hutton ML, Wszolek ZK. Fronto-temporal dementia and parkinsonism linked to chromosome 17 associated with tau gene mutations (FTDP-17T). In:Dickson D, eds. Neurodegeneration: the molecular pathology of dementia and movement disorders. Basel: ISN Neuropath Press, 2003.
  217. Morris HR, Osaki Y, Holton J, et al. Tau exon 10 +16 mutation FTDP-17 presenting clinically as sporadic young onset PSP. Neurology 2003;61:102-104.
  218. Spillantini MG, Yoshida H, Rizzini C, et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol 2000;48:939-943.
  219. Bugiani O, Murrell JR, Giaccone G, et al. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol 1999;58:667-677.
  220. Neumann M, Schulz-Schaeffer W, Crowther RA, et al. Pick's disease associated with the novel Tau gene mutation K369I. Ann Neurol 2001;50:503-513.
  221. Rosso SM, van Herpen E, Deelen W, et al. A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick's disease. Ann Neurol 2002;51:373-376.
  222. Bumke O, Foerster O. Allgemeine Neurologie I Anatomie. Berlin: Julius Springer, 1935.
  223. Truex RC, Carpenter MB. Human Neuroanatomy. Baltimore: Williams & Wilkins, 1969.
  224. Carpenter MB. Human neuroanatomy. Baltimore: Williams & Wilkins, 1976.
  225. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Ann Neurol 1992;42:631-639.
  226. Bierer LM, Hof PR, Purohit DP, et al. Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995;52:81-88.
  227. Duyckaerts C, Bennecib M, Grignon Y, et al. Modeling the relation between neurofibrillary tangles and intellectual status. Neurobiol Aging 1997;18:267-273.
  228. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998;95:55-66.
  229. Sisodia SS. Nuclear inclusions in glutamine repeat disorders: are they pernicious, coincidental, or beneficial? Cell 1998;95:1-4.
  230. Graff-Radford NR, Damasio AR, Hyman BT, et al. Progressive aphasia in a patient with Pick's disease: a neuropsychological, radiologic and anatomic study. Neurology 1990;40:620-626.

Was this article helpful?

0 0

Post a comment